{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:27:16Z","timestamp":1793608036866,"version":"4.5.0"},"reference-count":222,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC2309801"],"award-info":[{"award-number":["2024YFC2309801"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC2309802"],"award-info":[{"award-number":["2024YFC2309802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L242117"],"award-info":[{"award-number":["L242117"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.128992","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:16:00Z","timestamp":1789121760000},"page":"128992","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["T-cell immunity in human herpesvirus vaccine development: research advances and translational challenges"],"prefix":"10.1016","volume":"92","author":[{"given":"Yuxin","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengde","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128992_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.vaccine.2026.128992_bb0010","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41467-022-29307-3","article-title":"Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank","volume":"13","author":"Mentzer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128992_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0020","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/jcm.27.4.651-653.1989","article-title":"Seroepidemiology of human herpesvirus 6 infection in normal children and adults","volume":"27","author":"Okuno","year":"1989","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0025","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/jvi.65.11.6260-6265.1991","article-title":"Human herpesvirus 7: antigenic properties and prevalence in children and adults","volume":"65","author":"Wyatt","year":"1991","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0030","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1017\/S0950268817001546","article-title":"A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data","volume":"145","author":"Bollaerts","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.vaccine.2026.128992_bb0035","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/jmv.27538","article-title":"The global disease burden of varicella-zoster virus infection from 1990 to 2019","volume":"94","author":"Huang","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/scbi.1998.0089","article-title":"Seroepidemiology of Kaposi\u2019s sarcoma-associated herpesvirus (KSHV)","volume":"9","author":"Chatlynne","year":"1999","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0045","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","article-title":"Overview of classification","author":"Davison","year":"2007"},{"key":"10.1016\/j.vaccine.2026.128992_bb0050","doi-asserted-by":"crossref","first-page":"e179483","DOI":"10.1172\/JCI179483","article-title":"Therapeutic vaccines for herpesviruses","volume":"134","author":"Cohen","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vaccine.2026.128992_bb0055","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3389\/fimmu.2019.02110","article-title":"The roles of host and viral antibody Fc receptors in herpes simplex virus (HSV) and human cytomegalovirus (HCMV) infections and immunity","volume":"10","author":"Jenks","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0060","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2019.02.009","article-title":"Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine","volume":"59","author":"Heineman","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0070","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0075","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128992_bb0080","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.18.1.275","article-title":"CD8+ T cell effector mechanisms in resistance to infection","volume":"18","author":"Harty","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.immunol.15.1.405","article-title":"Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection","volume":"15","author":"Rickinson","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1084\/jem.193.3.405","article-title":"Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells","volume":"193","author":"Subklewe","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2026.128992_bb0100","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb0105","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1126\/science.1088902","article-title":"Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1","volume":"301","author":"Yin","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128992_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001151","article-title":"Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation","volume":"6","author":"Apcher","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb0115","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1074-7613(00)80397-0","article-title":"Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing","volume":"7","author":"Blake","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128992_bb0120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20031219","article-title":"Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes","volume":"199","author":"Voo","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2026.128992_bb0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virol.2012.09.012","article-title":"Anti-viral CD8 T cells and the cytokines that they love","volume":"435","author":"Cox","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.128992_bb0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1615\/CritRevImmunol.2013007909","article-title":"Regulation of antiviral CD8 T-cell responses","volume":"33","author":"Kulinski","year":"2013","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.735643","article-title":"Tissue-resident-memory CD8(+) T cells bridge innate immune responses in neighboring epithelial cells to control human genital herpes","volume":"12","author":"Peng","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0140","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128992_bb0145","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.4049\/jimmunol.178.5.2844","article-title":"CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help","volume":"178","author":"Hernandez","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0150","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1084\/jem.20130097","article-title":"CD4+ T helper cells use CD154-CD40 interactions to counteract T reg cell-mediated suppression of CD8+ T cell responses to influenza","volume":"210","author":"Ballesteros-Tato","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2026.128992_bb0155","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1128\/JVI.06573-11","article-title":"Human CD4+ T cell response to human herpesvirus 6","volume":"86","author":"Nastke","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0160","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2012-05-430413","article-title":"Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation","volume":"121","author":"Gerdemann","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128992_bb0165","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2003-03-0930","article-title":"Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1","volume":"103","author":"Landais","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128992_bb0170","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1349-7006.2008.00852.x","article-title":"Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells","volume":"99","author":"Demachi-Okamura","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.vaccine.2026.128992_bb0175","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1084\/jem.20052246","article-title":"Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation","volume":"203","author":"Casazza","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.vaccine.2026.128992_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005832","article-title":"Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-specific CD4+ T cells targeted to vascular endothelium","volume":"12","author":"Pachnio","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb0185","article-title":"Human cytomegalovirus (HCMV)-specific CD4(+) T cells are polyfunctional and can respond to HCMV-infected dendritic cells in vitro","volume":"91:e02128-16","author":"Jackson","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0190","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1074-7613(03)00112-2","article-title":"Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia","volume":"18","author":"Khanna","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128992_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867962","article-title":"HSV-2-specific human female reproductive tract tissue resident memory T cells recognize diverse HSV antigens","volume":"13","author":"Koelle","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0200","doi-asserted-by":"crossref","first-page":"e173489","DOI":"10.1172\/jci.insight.173489","article-title":"Epstein-Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues","volume":"9","author":"Kirchmeier","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2026.128992_bb0205","doi-asserted-by":"crossref","first-page":"eady8316","DOI":"10.1126\/sciadv.ady8316","article-title":"CXCR5 identifies stem-like resident memory CD8(+) T cells enriched for latent EBV specificity in tonsils","volume":"12","author":"Rivera Ballesteros","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.vaccine.2026.128992_bb0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fimmu.2017.00105","article-title":"Gammadelta T cell-mediated immunity to cytomegalovirus infection","volume":"8","author":"Khairallah","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0215","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/infdis\/161.5.1013","article-title":"Gamma delta T cell receptor-bearing lymphocytes during Epstein-Barr virus infection","volume":"161","author":"De Paoli","year":"1990","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102305","article-title":"Alphabeta and gammadelta T-cell responses to Epstein-Barr virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients","volume":"82","author":"Eiz-Vesper","year":"2023","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0225","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.4049\/jimmunol.180.5.3417","article-title":"Gamma delta+ T cells involvement in viral immune control of chronic human herpesvirus 8 infection","volume":"180","author":"Barcy","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0230","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2013-01-480665","article-title":"Innate immune control of EBV-infected B cells by invariant natural killer T cells","volume":"122","author":"Chung","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128992_bb0235","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2015.00312","article-title":"CD1d expression and invariant NKT cell responses in herpesvirus infections","volume":"6","author":"Chung","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10059-013-0221-8","article-title":"Human cytomegalovirus (HCMV) US2 protein interacts with human CD1d (hCD1d) and down-regulates invariant NKT (iNKT) cell activity","volume":"36","author":"Han","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.vaccine.2026.128992_bb0245","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1002\/j.1460-2075.1996.tb00689.x","article-title":"Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47","volume":"15","author":"Ahn","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.vaccine.2026.128992_bb0250","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1128\/jvi.71.4.2970-2979.1997","article-title":"Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains","volume":"71","author":"Jones","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0255","first-page":"37","article-title":"The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol","volume":"269","author":"van der Wal","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0260","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0092-8674(00)81054-5","article-title":"The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol","volume":"84","author":"Wiertz","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128992_bb0265","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.4049\/jimmunol.0803218","article-title":"Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation","volume":"182","author":"Horst","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0270","doi-asserted-by":"crossref","first-page":"41402","DOI":"10.1074\/jbc.M111.237784","article-title":"Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP","volume":"286","author":"Wycisk","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vaccine.2026.128992_bb0275","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/JVI.79.2.841-852.2005","article-title":"Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion","volume":"79","author":"Ressing","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0280","doi-asserted-by":"crossref","first-page":"7655","DOI":"10.1128\/JVI.77.13.7655-7662.2003","article-title":"Mutational analysis of the HLA class II interaction with Epstein-Barr virus glycoprotein 42","volume":"77","author":"McShane","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0285","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/pathogens11080831","article-title":"CD4+ cytotoxic T cells involved in the development of EBV-associated diseases","volume":"11","author":"Ruiz-Pablos","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2026.128992_bb0290","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/rmv.1791","article-title":"Immune escape of gamma-herpesviruses from adaptive immunity","volume":"24","author":"Hu","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0295","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1128\/JVI.02123-10","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression","volume":"85","author":"Schmidt","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003751","article-title":"IRF-4-mediated CIITA transcription is blocked by KSHV encoded LANA to inhibit MHC II presentation","volume":"9","author":"Cai","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002704","article-title":"The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination","volume":"8","author":"Jochum","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb0310","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/viro.2002.1716","article-title":"Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV","volume":"304","author":"Salek-Ardakani","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.128992_bb0315","doi-asserted-by":"crossref","first-page":"E6467","DOI":"10.1073\/pnas.1605884113","article-title":"Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells","volume":"113","author":"Albanese","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128992_bb0320","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12250-017-3996-5","article-title":"An update: Epstein-Barr virus and immune evasion via microRNA regulation","volume":"32","author":"Zuo","year":"2017","journal-title":"Virol. Sin."},{"key":"10.1016\/j.vaccine.2026.128992_bb0325","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1471-2407-6-283","article-title":"Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9","volume":"6","author":"Keryer-Bibens","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2026.128992_bb0330","doi-asserted-by":"crossref","first-page":"10334","DOI":"10.1128\/JVI.01310-13","article-title":"Exosomes derived from Epstein-Barr virus-infected cells are internalized via caveola-dependent endocytosis and promote phenotypic modulation in target cells","volume":"87","author":"Nanbo","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0335","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/0008-5472.CAN-04-2552","article-title":"Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation","volume":"65","author":"Voo","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb0340","doi-asserted-by":"crossref","first-page":"e001588","DOI":"10.1136\/jitc-2020-001588","article-title":"EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells","volume":"8","author":"Huo","year":"2020","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.vaccine.2026.128992_bb0345","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1089\/aid.2016.0155","article-title":"Regulatory T cell effect on CD8(+) T cell responses to human herpesvirus 8 infection and development of Kaposi\u2019s sarcoma","volume":"33","author":"Lepone","year":"2017","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.vaccine.2026.128992_bb0350","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.3390\/ijms24097813","article-title":"T-cells subsets in castleman disease: analysis of 28 cases including unicentric, multicentric and HHV8-related clinical forms","volume":"24","author":"Fraticelli","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vaccine.2026.128992_bb0355","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","year":"2007"},{"key":"10.1016\/j.vaccine.2026.128992_bb0360","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/13550289709030745","article-title":"The latency associated transcripts (LAT) of herpes simplex virus: still no end in sight","volume":"3","author":"Block","year":"1997","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0365","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1128\/JVI.72.6.5067-5075.1998","article-title":"Herpes simplex virus type 1 latency-associated transcripts suppress viral replication and reduce immediate-early gene mRNA levels in a neuronal cell line","volume":"72","author":"Mador","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0370","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/microorganisms12020262","article-title":"A revision of herpes simplex virus type 1 transcription: first, repress; then, express","volume":"12","author":"Dunn","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2026.128992_bb0375","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2249.2011.04502.x","article-title":"Immunology in the clinic review series; focus on host responses: T cell responses to herpes simplex viruses","volume":"167","author":"Laing","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0380","doi-asserted-by":"crossref","first-page":"e00535-18","DOI":"10.1128\/JVI.00535-18","volume":"92","author":"Khan","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0385","doi-asserted-by":"crossref","first-page":"e02309-18","DOI":"10.1128\/JVI.02309-18","volume":"93","author":"Srivastava","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0390","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1574-6976.2011.00320.x","article-title":"The molecular basis of herpes simplex virus latency","volume":"36","author":"Nicoll","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.vaccine.2026.128992_bb0395","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.vaccine.2026.128992_bb0400","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0405","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41467-018-03569-2","article-title":"A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61","volume":"9","author":"Depledge","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128992_bb0410","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1038\/s41467-020-20031-4","article-title":"Varicella-zoster virus VLT-ORF63 fusion transcript induces broad viral gene expression during reactivation from neuronal latency","volume":"11","author":"Ouwendijk","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128992_bb0415","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/infdis\/jiy403","article-title":"Immunobiology of Varicella-Zoster Virus Infection","volume":"218","author":"Laing","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0420","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","article-title":"The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase I clinical trial and two-year follow-up","volume":"64","author":"Si","year":"2016","journal-title":"Chem Pharm Bull (Tokyo)."},{"key":"10.1016\/j.vaccine.2026.128992_bb0425","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128992_bb0430","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3026(15)00246-X","article-title":"Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial","volume":"3","author":"Nakamura","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0435","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/M19-2511","article-title":"Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized Clinical Trial","volume":"172","author":"Aldoss","year":"2020","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.vaccine.2026.128992_bb0440","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","article-title":"Safety and immunogenicity of a messenger RNA-based cytomegalovirus vaccine in healthy adults: results from a phase 1 randomized clinical trial","volume":"230","author":"Fierro","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0445","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/pathogens9070590","article-title":"Understanding HCMV latency using unbiased proteomic analyses","volume":"9","author":"Poole","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2026.128992_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003635","article-title":"Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4(+) T cells","volume":"9","author":"Mason","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb0455","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2217\/fmb.10.61","article-title":"Human herpesvirus-6 entry into host cells","volume":"5","author":"Tang","year":"2010","journal-title":"Future Microbiol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0460","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/1348-0421.12110","article-title":"Human herpesvirus-6A gQ1 and gQ2 are critical for human CD46 usage","volume":"58","author":"Jasirwan","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0465","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/v9070194","article-title":"Latency, integration, and reactivation of human herpesvirus-6","volume":"9","author":"Pantry","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128992_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008609","article-title":"Tetrameric glycoprotein complex gH\/gL\/gQ1\/gQ2 is a promising vaccine candidate for human herpesvirus 6B","volume":"16","author":"Wang","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb0475","doi-asserted-by":"crossref","first-page":"4697529","DOI":"10.1155\/2020\/4697529","article-title":"Comprehensive screening of mouse T-cell epitopes in human herpesvirus 6B glycoprotein H\/L\/Q1\/Q2 tetramer complex","volume":"2020","author":"Okutani","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb0480","doi-asserted-by":"crossref","first-page":"13911","DOI":"10.1073\/pnas.95.23.13911","article-title":"U94 of human herpesvirus 6 is expressed in latently infected peripheral blood mononuclear cells and blocks viral gene expression in transformed lymphocytes in culture","volume":"95","author":"Rotola","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128992_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0928-0197(95)00005-S","article-title":"Human herpesvirus-7 (HHV-7): current status","volume":"4","author":"Ablashi","year":"1995","journal-title":"Clin. Diagn. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0490","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1099-1654(199910\/12)9:4<245::AID-RMV253>3.0.CO;2-I","article-title":"Human herpesvirus 7","volume":"9","author":"Black","year":"1999","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0495","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00437-24","article-title":"Update on human herpesvirus 7 pathogenesis and clinical aspects as a roadmap for future research","volume":"98","author":"Verbeek","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0500","doi-asserted-by":"crossref","first-page":"8725","DOI":"10.1128\/JVI.72.11.8725-8730.1998","article-title":"Definition and distribution analysis of glycoprotein B gene alleles of human herpesvirus 7","volume":"72","author":"Franti","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0505","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1348-0421.1997.tb01171.x","article-title":"Characterization of glycoprotein H and L of human herpesvirus 7","volume":"41","author":"Mukai","year":"1997","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0510","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/JVI.75.2.891-902.2001","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays","volume":"75","author":"Jenner","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0515","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1128\/JVI.74.13.6207-6212.2000","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus open reading frame 50\/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line","volume":"74","author":"Gradoville","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0520","doi-asserted-by":"crossref","first-page":"14457","DOI":"10.1128\/JVI.79.22.14457-14464.2005","article-title":"Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi\u2019s sarcoma-associated herpesvirus originate from a common promoter","volume":"79","author":"Pearce","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0525","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.3390\/v6124961","article-title":"KSHV LANA--the master regulator of KSHV latency","volume":"6","author":"Uppal","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128992_bb0530","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02913-24","article-title":"Development of KSHV vaccine platforms and chimeric MHV68-K-K8.1 glycoprotein for evaluating the in vivo immunogenicity and efficacy of KSHV vaccine candidates","volume":"15","author":"Yang","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2026.128992_bb0535","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0540","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.3390\/ijms21207561","article-title":"Unconventional peptide presentation by classical MHC class I and implications for T and NK cell activation","volume":"21","author":"Zajonc","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.vaccine.2026.128992_bb0545","doi-asserted-by":"crossref","first-page":"18.19.1","DOI":"10.1002\/cpim.12","article-title":"TepiTool: a pipeline for computational prediction of T cell epitope candidates","volume":"114","author":"Paul","year":"2016","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0550","doi-asserted-by":"crossref","first-page":"W526","DOI":"10.1093\/nar\/gkae407","article-title":"Next-generation IEDB tools: a platform for epitope prediction and analysis","volume":"52","author":"Yan","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb0555","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.4161\/hv.26088","article-title":"Advances in the study of HLA-restricted epitope vaccines","volume":"9","author":"Zhao","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128992_bb0560","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/fvl.12.108","article-title":"Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications","volume":"7","author":"Testa","year":"2012","journal-title":"Future Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0565","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","article-title":"Present yourself! By MHC class I and MHC class II molecules","volume":"37","author":"Rock","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0570","doi-asserted-by":"crossref","first-page":"e01193-19","DOI":"10.1128\/JVI.01193-19","article-title":"Herpes simplex virus 1-specific CD8(+) T cell priming and latent ganglionic retention are shaped by viral epitope promoter kinetics","volume":"94","author":"Treat","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0575","doi-asserted-by":"crossref","first-page":"11792","DOI":"10.1128\/JVI.00692-08","article-title":"Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B","volume":"82","author":"Chentoufi","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0580","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.4049\/jimmunol.1700851","article-title":"Cytomegalovirus (CMV) epitope-specific CD4(+) T cells are inflated in HIV(+) CMV(+) subjects","volume":"199","author":"Abana","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0585","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/cmi.2009.13","article-title":"Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes","volume":"6","author":"Wang","year":"2009","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0590","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.4049\/jimmunol.169.3.1593","article-title":"Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt\u2019s lymphoma cells","volume":"169","author":"Paludan","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0595","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3390\/cancers13040867","article-title":"Targeting CAR to the peptide-MHC complex reveals distinct signaling compared to that of TCR in a Jurkat T cell model","volume":"13","author":"Wu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.vaccine.2026.128992_bb0600","doi-asserted-by":"crossref","first-page":"e172092","DOI":"10.1172\/JCI172092","article-title":"An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model","volume":"134","author":"Wang","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vaccine.2026.128992_bb0605","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.vaccine.2026.128992_bb0610","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNgamma response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines."},{"key":"10.1016\/j.vaccine.2026.128992_bb0615","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/vaccines13050497","article-title":"A QS21 + CpG-adjuvanted trivalent HSV-2 vaccine and trivalent HSV-2 mRNA vaccine induce a strong immune response, protect against HSV-2 infection, and cross-protect against HSV-1 infection in mice","volume":"13","author":"Cao","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128992_bb0620","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12250-020-00261-y","article-title":"Immune responses to varicella-zoster virus glycoprotein E formulated with poly(lactic-co-glycolic acid) nanoparticles and nucleic acid adjuvants in mice","volume":"36","author":"Wang","year":"2021","journal-title":"Virol. Sin."},{"key":"10.1016\/j.vaccine.2026.128992_bb0625","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of defined TLR ligands as adjuvants within human vaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.vaccine.2026.128992_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.745016","article-title":"Exploration of pattern recognition receptor agonists as candidate adjuvants","volume":"11","author":"Ong","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0635","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.smim.2018.10.004","article-title":"Correlates of GLA family adjuvants\u2019 activities","volume":"39","author":"Reed","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0640","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0645","doi-asserted-by":"crossref","first-page":"21916","DOI":"10.1021\/acs.jmedchem.4c01801","article-title":"Enhancing COVID-19 vaccine efficacy: dual adjuvant strategies with TLR7\/8 agonists and glycolipids","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.vaccine.2026.128992_bb0650","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cell.2018.08.070","article-title":"The mevalonate pathway is a druggable target for vaccine adjuvant discovery","volume":"175","author":"Xia","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128992_bb0655","doi-asserted-by":"crossref","first-page":"1053872","DOI":"10.3389\/fbioe.2022.1053872","article-title":"Manganese-based nanoadjuvants for enhancement of immune effect of DNA vaccines","volume":"10","author":"Ma","year":"2022","journal-title":"Front Bioeng Biotechnol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0660","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1038\/s41467-023-39770-1","article-title":"Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice","volume":"14","author":"Dasari","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128992_bb0665","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI125364","article-title":"Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas","volume":"129","author":"Ruhl","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vaccine.2026.128992_bb0670","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nbt.1742","article-title":"Efficient mucosal vaccination mediated by the neonatal Fc receptor","volume":"29","author":"Ye","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0675","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/vaccines12101191","article-title":"Intranasal prime-boost with spike vectors generates antibody and T-cell responses at the site of SARS-CoV-2 infection","volume":"12","author":"Metko","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128992_bb0680","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154-155","author":"Samaridou","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.vaccine.2026.128992_bb0685","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/vaccines13090958","article-title":"A comparative study on immune protection efficacy: an HSV-1 trivalent antigen subunit vaccine formulated with a cellular immunity-inducing adjuvant versus an mRNA vaccine","volume":"13","author":"Cao","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128992_bb0690","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.virs.2022.06.002","article-title":"LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix in VZV-primed mice","volume":"37","author":"Luan","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.vaccine.2026.128992_bb0695","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fimmu.2014.00255","article-title":"Dendritic cell-targeted vaccines","volume":"5","author":"Cohn","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0700","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.6","article-title":"Targeting dendritic cells: a promising strategy to improve vaccine effectiveness","volume":"5","author":"Macri","year":"2016","journal-title":"Clin Transl Immunology."},{"key":"10.1016\/j.vaccine.2026.128992_bb0705","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-03-148072","article-title":"Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses","volume":"112","author":"Gurer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128992_bb0710","first-page":"849","article-title":"LMP2-DC vaccine elicits specific EBV-LMP2 response to effectively improve immunotherapy in patients with nasopharyngeal cancer","volume":"33","author":"Zeng","year":"2020","journal-title":"Biomed. Environ. Sci."},{"key":"10.1016\/j.vaccine.2026.128992_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104755","article-title":"Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa","volume":"177","author":"Kim","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb0720","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/vaccines13030271","article-title":"Immunogenicity and protective efficacy of an mRNA vaccine targeting HSV-2 UL41 in mice","volume":"13","author":"Mou","year":"2025","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.vaccine.2026.128992_bb0725","article-title":"mRNA-based vaccines targeting the T-cell epitope-rich domain of epstein barr virus latent proteins elicit robust anti-tumor immunity in mice","volume":"10","author":"Zhao","year":"2023","journal-title":"Adv Sci (Weinh)."},{"key":"10.1016\/j.vaccine.2026.128992_bb0730","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/14760584.2022.2029415","article-title":"Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines","volume":"21","author":"McFall-Boegeman","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2026.128992_bb0735","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1016\/j.vaccine.2011.09.046","article-title":"Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons","volume":"29","author":"Wald","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0740","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1016\/j.vaccine.2016.09.001","article-title":"Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1\/2a trial","volume":"34","author":"Flechtner","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0745","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.vaccine.2019.05.009","article-title":"Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0750","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/vaccines13090908","article-title":"The path towards effective long-lasting tissue-targeted prime\/pull\/keep herpes simplex therapeutic vaccines","volume":"13","author":"Quadiri","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128992_bb0755","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00135-25","article-title":"A tissue-targeted prime\/pull\/keep therapeutic herpes simplex virus vaccine protects against recurrent ocular herpes infection and disease in HLA-A*0201 transgenic rabbits","volume":"99","author":"Chentoufi","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0760","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/hum.2008.033","article-title":"Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines","volume":"19","author":"Lin","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.vaccine.2026.128992_bb0765","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.849515","article-title":"Combinatorial herpes simplex vaccine strategies: from bedside to bench and back","volume":"13","author":"Chentoufi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0770","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.vaccine.2015.10.137","article-title":"A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs","volume":"34","author":"Odegard","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0775","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01596-23","volume":"98","author":"Quadiri","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0780","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jix004","article-title":"Therapeutic vaccine for genital herpes simplex virus-2 infection: findings from a randomized trial","volume":"215","author":"Bernstein","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0785","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiy415","article-title":"Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex virus-2, on viral shedding and lesions: results of a randomized placebo-controlled trial","volume":"218","author":"Van Wagoner","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0790","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/CVI.00167-08","article-title":"Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system","volume":"15","author":"Cattamanchi","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0795","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1080\/21645515.2016.1221872","article-title":"An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes simplex virus DNA vaccine, COR-1","volume":"12","author":"Dutton","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128992_bb0800","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226320","article-title":"Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: a randomized double blinded phase I\/IIa trial","volume":"14","author":"Chandra","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128992_bb0805","doi-asserted-by":"crossref","first-page":"eaaw7083","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0810","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008795","article-title":"An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection","volume":"16","author":"Egan","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb0815","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3390\/v15071483","article-title":"A trivalent HSV-2 gC2, gD2, gE2 nucleoside-modified mRNA-LNP vaccine provides outstanding protection in mice against genital and non-genital HSV-1 infection, comparable to the same antigens derived from HSV-1","volume":"15","author":"Egan","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128992_bb0820","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiz225","article-title":"A randomized, double-blinded, placebo-controlled, phase 1 study of a replication-defective herpes simplex virus (HSV) type 2 vaccine, HSV529, in adults with or without HSV infection","volume":"220","author":"Dropulic","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127821","article-title":"Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infection","volume":"65","author":"Laing","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0855","doi-asserted-by":"crossref","first-page":"1419634","DOI":"10.3389\/fimmu.2024.1419634","article-title":"A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0830","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128992_bb0835","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.vaccine.2026.128992_bb1110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128992_bb0860","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0865","doi-asserted-by":"crossref","first-page":"2495607","DOI":"10.1080\/21645515.2025.2495607","article-title":"Varicella zoster virus mRNA vaccine candidate induced superior cellular immunity and comparable humoral and Fc-mediated immunity compared to the licensed subunit vaccine in a mouse model","volume":"21","author":"Jang","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128992_bb0870","doi-asserted-by":"crossref","first-page":"2309985","DOI":"10.1080\/22221751.2024.2309985","article-title":"Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques","volume":"13","author":"Huang","year":"2024","journal-title":"Emerg Microbes Infect."},{"key":"10.1016\/j.vaccine.2026.128992_bb0875","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128992_bb0880","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1473-3099(19)30310-X","article-title":"Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial","volume":"19","author":"Mullane","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0885","article-title":"Immunogenicity of inactivated varicella zoster vaccine in autologous hematopoietic stem cell transplant recipients and patients with solid or hematologic cancer. Open forum","author":"Boeckh","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.vaccine.2026.128992_bb0890","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128992_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104720","article-title":"Current understanding of human herpesvirus 6 (HHV-6) chromosomal integration","volume":"176","author":"Aimola","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb0845","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/bmt.2015.76","article-title":"Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know","volume":"50","author":"Ogata","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.vaccine.2026.128992_bb0850","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1373\/clinchem.2013.217240","article-title":"Identification of chromosomally integrated human herpesvirus 6 by droplet digital PCR","volume":"60","author":"Sedlak","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.vaccine.2026.128992_bb0895","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3748\/wjg.v11.i5.629","article-title":"Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas","volume":"11","author":"Luo","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0900","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb0905","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/vaccines7020044","article-title":"Novel synthetic DNA immunogens targeting latent expressed antigens of Epstein-Barr Virus elicit potent cellular responses and inhibit tumor growth","volume":"7","author":"Wojtak","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128992_bb0910","doi-asserted-by":"crossref","first-page":"2412640","DOI":"10.1080\/22221751.2024.2412640","article-title":"TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice","volume":"13","author":"Zhang","year":"2024","journal-title":"Emerg Microbes Infect."},{"key":"10.1016\/j.vaccine.2026.128992_bb0915","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12951-023-02069-w","article-title":"LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion","volume":"21","author":"Xiang","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0920","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1007\/s12274-022-5254-x","article-title":"A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma","volume":"16","author":"Guo","year":"2023","journal-title":"Nano Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb0925","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.05598-11","article-title":"A virus-like particle-based Epstein-Barr virus vaccine","volume":"85","author":"Ruiss","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb0930","doi-asserted-by":"crossref","first-page":"19255","DOI":"10.18632\/oncotarget.13770","article-title":"Novel Epstein-Barr virus-like particles incorporating gH\/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice","volume":"8","author":"Perez","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2026.128992_bb0935","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007464","article-title":"Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice","volume":"14","author":"van Zyl","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb0940","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/vaccines9060555","article-title":"Targeted delivery of BZLF1 to DEC205 drives EBV-protective immunity in a spontaneous model of EBV-driven lymphoproliferative disease","volume":"9","author":"Ahmed","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128992_bb0945","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.vaccine.2026.128992_bb0950","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s43018-025-00998-z","article-title":"A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial","volume":"6","author":"Thompson","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.vaccine.2026.128992_bb0955","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3324\/haematol.2023.284544","article-title":"A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant","volume":"109","author":"Nakamura","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.vaccine.2026.128992_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100787","article-title":"A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients","volume":"33","author":"Ljungman","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0965","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0970","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.vaccine.2026.128992_bb0975","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128992_bb0980","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","article-title":"MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults","volume":"129","author":"La Rosa","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128992_bb0985","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/infdis\/jiaa121","article-title":"A randomized dose-escalating phase I trial of a replication-deficient lymphocytic choriomeningitis virus vector-based vaccine against human cytomegalovirus","volume":"225","author":"Schwendinger","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb0990","doi-asserted-by":"crossref","first-page":"13645","DOI":"10.1073\/pnas.1511526112","article-title":"Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission","volume":"112","author":"Bialas","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128992_bb0995","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003383","article-title":"Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion","volume":"9","author":"Ameres","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128992_bb1000","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/v4071116","article-title":"T cell memory in the context of persistent herpes viral infections","volume":"4","author":"Torti","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128992_bb1005","first-page":"705","article-title":"Epstein-Barr virus and HLA-DPB1-*0301 in young adult Hodgkin\u2019s disease: evidence for inherited susceptibility to Epstein-Barr virus in cases that are EBV(+ve)","volume":"10","author":"Alexander","year":"2001","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.vaccine.2026.128992_bb1010","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ijc.29467","article-title":"Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis","volume":"137","author":"Johnson","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.vaccine.2026.128992_bb1015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.humimm.2014.04.016","article-title":"Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine","volume":"75","author":"Samandary","year":"2014","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.vaccine.2026.128992_bb1020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb1025","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European conference on infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb1030","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/febs.15756","article-title":"Dampening antiviral immunity can protect the host","volume":"289","author":"Panetti","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.vaccine.2026.128992_bb1035","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1080\/21645515.2016.1222341","article-title":"The safety of maternal immunization","volume":"12","author":"Regan","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128992_bb1040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128992_bb1045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221797120","article-title":"Genomic and geographical structure of human cytomegalovirus","volume":"120","author":"Charles","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128992_bb1050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.12.005","article-title":"Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi\u2019s sarcoma lesions during pre-AIDS and AIDS era","volume":"398","author":"Tornesello","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2026.128992_bb1055","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/infdis\/jiy427","article-title":"Genome-wide sequence analysis of kaposi sarcoma-associated herpesvirus shows diversification driven by recombination","volume":"218","author":"Sallah","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128992_bb1060","doi-asserted-by":"crossref","first-page":"e001513","DOI":"10.1136\/jitc-2020-001513","article-title":"Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model","volume":"8","author":"Park","year":"2020","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.vaccine.2026.128992_bb1065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7774\/cevr.2024.13.1.10","article-title":"Humanized mouse model for vaccine evaluation: an overview","volume":"13","author":"Kaushik","year":"2024","journal-title":"Clin Exp Vaccine Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb1070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-7580-5-3","article-title":"Of mice and humans: how good are HLA transgenic mice as a model of human immune responses?","volume":"5","author":"Kotturi","year":"2009","journal-title":"Immunome Res."},{"key":"10.1016\/j.vaccine.2026.128992_bb1075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/21645515.2015.1103405","article-title":"Generation of human MHC (HLA-A11\/DR1) transgenic mice for vaccine evaluation","volume":"12","author":"Zeng","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128992_bb1080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.coviro.2017.07.026","article-title":"Humanized mouse models for Epstein Barr virus infection","volume":"25","author":"Munz","year":"2017","journal-title":"Curr Opin Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb1085","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coviro.2017.08.005","article-title":"Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections","volume":"25","author":"Itell","year":"2017","journal-title":"Curr Opin Virol."},{"key":"10.1016\/j.vaccine.2026.128992_bb1090","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01132-25","article-title":"Organoids: physiologically relevant ex vivo models for viral disease research","volume":"99","author":"Wang","year":"2025","journal-title":"J. Virol."},{"issue":"SI","key":"10.1016\/j.vaccine.2026.128992_bb1095","doi-asserted-by":"crossref","first-page":"vlaf075","DOI":"10.1093\/immhor\/vlaf075","article-title":"Screening for next generation vaccines in human immune organoids","volume":"9","author":"Chen","year":"2025","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.vaccine.2026.128992_bb1100","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/vaccines13070687","article-title":"The application of single-cell technologies for vaccine development against viral infections","volume":"13","author":"Nguyen","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128992_bb1105","doi-asserted-by":"crossref","first-page":"2597629","DOI":"10.1080\/21645515.2025.2597629","article-title":"mRNA vaccine platforms and novel delivery systems: from mechanistic principles to clinical translation","volume":"21","author":"Yang","year":"2025","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:40:15Z","timestamp":1793605215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26008017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":222,"alternative-id":["S0264410X26008017"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128992","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell immunity in human herpesvirus vaccine development: research advances and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128992","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128992"}}